Nanogen Company

Nanogen, Inc., a diagnostics company, engages in developing, manufacturing, and selling diagnostic products for use in the in vitro diagnostic market in the United States, Canada, and Europe. It offers diagnostic test kits and reagents based on polymerase chain reaction (PCR) technology in the molecular diagnostic market. The company’s PCR molecular product lines comprise Q-PCR Alert products for in-vitro diagnostic use, and are sold in Italy via a contract sales force and in other European countries through a network of distributors; and MGB Alert products. It also offers point-of-care products, which include qualitative cardiac test products that are rapid test assays used in emergency care settings for the diagnosis of myocardial infarction; quantitative cardiac tests, a quantitative test measuring the concentration of the peptide NT-proBNP for the diagnosis of congestive heart failure; and pandemic influenza test that detects and differentiates the various strains of influenza, including potential pandemic strains.
The company was founded in 1993 and is headquartered in San Diego, California. On May 13, 2009, Nanogen, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware.
Technology: undisclosed
Industry: Precision Medicine
Headquarters: San Diego
Founded Date: 1993
Employees Number: Undisclosed
Funding Status: undisclosed

Visit Website
Register and Claim Ownership